Literature DB >> 28094848

The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.

Mahul B Amin1, Frederick L Greene2, Stephen B Edge3,4, Carolyn C Compton5,6, Jeffrey E Gershenwald7, Robert K Brookland8, Laura Meyer9, Donna M Gress10, David R Byrd11, David P Winchester12.   

Abstract

The American Joint Committee on Cancer (AJCC) staging manual has become the benchmark for classifying patients with cancer, defining prognosis, and determining the best treatment approaches. Many view the primary role of the tumor, lymph node, metastasis (TNM) system as that of a standardized classification system for evaluating cancer at a population level in terms of the extent of disease, both at initial presentation and after surgical treatment, and the overall impact of improvements in cancer treatment. The rapid evolution of knowledge in cancer biology and the discovery and validation of biologic factors that predict cancer outcome and response to treatment with better accuracy have led some cancer experts to question the utility of a TNM-based approach in clinical care at an individualized patient level. In the Eighth Edition of the AJCC Cancer Staging Manual, the goal of including relevant, nonanatomic (including molecular) factors has been foremost, although changes are made only when there is strong evidence for inclusion. The editorial board viewed this iteration as a proactive effort to continue to build the important bridge from a "population-based" to a more "personalized" approach to patient classification, one that forms the conceptual framework and foundation of cancer staging in the era of precision molecular oncology. The AJCC promulgates best staging practices through each new edition in an effort to provide cancer care providers with a powerful, knowledge-based resource for the battle against cancer. In this commentary, the authors highlight the overall organizational and structural changes as well as "what's new" in the Eighth Edition. It is hoped that this information will provide the reader with a better understanding of the rationale behind the aggregate proposed changes and the exciting developments in the upcoming edition. CA Cancer J Clin 2017;67:93-99.
© 2017 American Cancer Society. © 2017 American Cancer Society.

Entities:  

Keywords:  American Joint Committee on Cancer (AJCC); TNM staging; application programing interface; cancer stage; component content management system; electronic health record; precision medicine; prognostic factors; risk assessment models

Mesh:

Year:  2017        PMID: 28094848     DOI: 10.3322/caac.21388

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  1128 in total

1.  The Clinical Significance of Lymphovascular Invasion in Gastric Cancer.

Authors:  Hirohito Fujikawa; Keisuke Koumori; Hayato Watanabe; Kazuki Kano; Yyta Shimoda; Toru Aoyama; Takanobu Yamada; Tamagawa Hiroshi; Naoto Yamamoto; Haruhiko Cho; Manabu Shiozawa; Takaki Yoshikawa; Souichiro Morinaga; Yasushi Rino; Munetaka Masuda; Takashi Ogata; Takashi Oshima
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Primary tumor volume as a predictor of distant metastases and survival in patients with sinonasal mucosal melanoma.

Authors:  Stephanie Flukes; Shivangi Lohia; Christopher A Barker; Jennifer R Cracchiolo; Ian Ganly; Snehal G Patel; Benjamin R Roman; Jatin P Shah; Alexander N Shoushtari; Viviane Tabar; Akash Shah; Marc A Cohen
Journal:  Head Neck       Date:  2020-08-01       Impact factor: 3.147

3.  Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation.

Authors:  Yoshikuni Kawaguchi; Heather A Lillemoe; Elena Panettieri; Yun Shin Chun; Ching-Wei D Tzeng; Thomas A Aloia; Scott Kopetz; Jean-Nicolas Vauthey
Journal:  J Am Coll Surg       Date:  2019-05-02       Impact factor: 6.113

4.  Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment.

Authors:  Ayman J Oweida; Shilpa Bhatia; Benjamin Van Court; Laurel Darragh; Natalie Serkova; Sana D Karam
Journal:  J Vis Exp       Date:  2019-04-22       Impact factor: 1.355

5.  Prognostic Evaluation of the Site of Invasion in Pathological Stage T3a Renal Cell Carcinoma.

Authors:  Gu-Shun Lai; Jian-Ri Li; Shian-Shiang Wang; Chuan-Shu Chen; Chun-Kuang Yang; Sheng-Chun Hung; Chen-Li Cheng; Yen-Chuan Ou; Kun-Yuan Chiu
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

6.  HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: Metastatic pheochromocytomas and paragangliomas: proceedings of the MEN2019 workshop.

Authors:  Patricia L M Dahia; Roderick Clifton-Bligh; Anne-Paule Gimenez-Roqueplo; Mercedes Robledo; Camilo Jimenez
Journal:  Endocr Relat Cancer       Date:  2020-08       Impact factor: 5.678

7.  Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer.

Authors:  Amanda Jane Williams Gibson; Haocheng Li; Adrijana D'Silva; Roxana A Tudor; Anifat A Elegbede; Shannon Mary Otsuka; D Gwyn Bebb; Winson Y Cheung
Journal:  Med Oncol       Date:  2018-08-02       Impact factor: 3.064

8.  Association between CTLA-4 + 49A > G and - 318C > T single-nucleotide polymorphisms and susceptibility to thyroid neoplasm.

Authors:  Shabnam Abtahi; Fatemeh Izadi Jahromi; Mohammad Hossein Dabbaghmanesh; Mahyar Malekzadeh; Abbas Ghaderi
Journal:  Endocrine       Date:  2018-08-04       Impact factor: 3.633

9.  Lymph-node Epstein-Barr virus concentration in diagnosing cervical lymph-node metastasis in nasopharyngeal carcinoma.

Authors:  HuiFang Li; Can Huang; Qiuyan Chen; Chuan Peng; Rong Zhang; Jingxian Shen; Mingyuan Chen; Haiqiang Mai; Ruhai Zou
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-04-02       Impact factor: 2.503

10.  Thoracic recurrence in patients with curatively-resected colorectal cancer: incidence, risk factors, and value of chest CT as a postoperative surveillance tool.

Authors:  J H Lee; Chang Min Park; I Joo; Y J Suh; E J Hwang; H Kim; J M Goo
Journal:  Eur Radiol       Date:  2018-10-22       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.